Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma

J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):8-12. doi: 10.1007/s10227-003-5002-0.

Authors

Stephen K Richardson¹, Karen S McGinnis, Michael Shapiro, Michael S Lehrer, Ellen J Kim, Carmela C Vittorio, Jacqueline M Junkins Hopkins, Alain H Rook

Affiliation

¹ Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

PMID: 12958701
DOI: 10.1007/s10227-003-5002-0

No abstract available

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Bexarotene
Clinical Trials as Topic
Combined Modality Therapy
Humans
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use*
Interferon-alpha / administration & dosage
Interferon-alpha / therapeutic use*
Lymphoma, T-Cell, Cutaneous / drug therapy
Lymphoma, T-Cell, Cutaneous / immunology
Lymphoma, T-Cell, Cutaneous / mortality
Lymphoma, T-Cell, Cutaneous / therapy*
Photopheresis*
Sezary Syndrome / therapy
Skin Neoplasms / drug therapy
Skin Neoplasms / immunology
Skin Neoplasms / therapy
Tetrahydronaphthalenes / administration & dosage
Tetrahydronaphthalenes / therapeutic use*

Substances

Antineoplastic Agents
Immunologic Factors
Interferon-alpha
Tetrahydronaphthalenes
Bexarotene